Amphastar Pharmaceuticals, Inc. et al v. Momenta Pharmaceuticals, Inc. et al

  1. May 22, 2019

    Pharmas Want Verdict Axed To Settle IP, Antitrust Disputes

    Pharmaceutical companies Amphastar, Sandoz and Momenta told a Massachusetts federal court that they have resolved their sprawling antitrust and patent battles over generic blood thinners, as long as the court agrees to nix Amphastar's win in the patent case.

  2. April 10, 2019

    Sandoz Says Antitrust Row Can't Hinge On Drug Patent Case

    Amphastar Pharmaceuticals Inc. can't claim that a victory in an unresolved patent dispute should allow it to score a partial win on key claims of a separate antitrust suit accusing two rivals of blocking its generic blood thinners, Sandoz Inc. has told a Massachusetts federal judge.

  3. February 25, 2019

    Pharmas Inflating Info Leak To Unseat Patent Loss, Rival Says

    Amphastar Pharmaceuticals Inc. told a Massachusetts federal court that two rivals it accuses of antitrust violations are trying to concoct a "crime-fraud" narrative out of an accidental leak of confidential documents to upend Amphastar's two-year-old patent win in a parallel suit.

  4. February 20, 2019

    Amphastar Says Rivals' Patent Loss Is Antitrust Ammo

    Amphastar Pharmaceuticals Inc. has told a Massachusetts federal judge that a chunk of its antitrust suit alleging two rivals boxed it out of the market for generic blood thinners has already been resolved in the drugmakers' separate patent dispute, pushing the court for a partial win on those claims.

  5. February 05, 2019

    Ex-Akin Gump Atty Leaked Docs In Antitrust Suit, Co. Says

    Amphastar Pharmaceuticals Inc. acknowledged Monday that its chief executive received a defendant's confidential documents in violation of a protective order in an antitrust suit, but argued the misstep by its outside counsel from Akin Gump Strauss Hauer & Feld LLP does not warrant "far-reaching and punitive" sanctions.

  6. June 01, 2018

    Momenta, Sandoz Denied Mid-Suit Antitrust Claims Appeal

    Momenta Pharmaceuticals Inc. and Sandoz Inc. cannot ask the First Circuit to opine on the validity of an antitrust case against them because the generic-drug companies' legal questions are inseparable from factual ones, a federal judge ruled Friday.

  7. April 18, 2018

    Momenta, Sandoz Ask To Appeal Antitrust Claims Mid-Suit

    Generic-drug companies Sandoz Inc. and Momenta Pharmaceuticals Inc. asked a federal judge for permission Tuesday to appeal mid-suit his decision to let another generic-drug maker sue them for allegedly telling regulators white lies to gain an advantage in a race to sell an alternative to brand-name blood thinner Lovenox.

  8. March 20, 2018

    Momenta, Sandoz Can't Dodge Amphastar Antitrust Suit

    A Massachusetts federal judge Monday declined a bid by Momenta Pharmaceuticals Inc. and Sandoz Inc. to toss a suit by Amphastar Pharmaceuticals, ruling that the plaintiff company had made a reasonable case that it was harmed by their alleged stifling of competition for a generic anticoagulant.

  9. May 05, 2017

    Amphastar Fights Momenta, Sandoz Bid To Duck Antitrust Suit

    Amphastar Pharmaceuticals Inc. urged a Massachusetts federal court on Thursday not to toss its already revived antitrust suit alleging Momenta Pharmaceuticals Inc. and Sandoz Inc. stifled competition for the generic anticoagulant enoxaparin, saying its adversaries just disagree with the facts.

  10. April 20, 2017

    Momenta, Sandoz Again Try To Nix Amphastar's Antitrust Suit

    Momenta and Sandoz on Thursday asked a Massachusetts federal judge to toss a revived antitrust suit by Amphastar claiming they stifled competition for generic anticoagulant enoxaparin, saying there have been no barriers to selling the drug.

Hello! I'm Law360's automated support bot.

How can I help you today?

For example, you can type:
  • I forgot my password
  • I took a free trial but didn't get a verification email
  • How do I sign up for a newsletter?
Ask a question!